Anti-tumor effect of berberine hydrochloride combined with epirubicin and cisplatin on advanced endometrial carcinoma / 国际肿瘤学杂志

ABSTRACT

Objective:To observe the anti-tumor effect of berberine hydrochloride combined with epirubicin and cisplatin on advanced endometrial carcinoma (EC).Methods:A total of 120 patients with advanced EC admitted to Chaohu Hospital of Anhui Medical University from January 2016 to December 2018 were enrolled. The patients were divided into experimental group and control group by random number table method, 60 cases in each group. The control group was given intravenous infusion of epirubicin and cisplatin. The experimental group was given oral berberine hydrochloride on the basis of control group treatment, 21 days/cycle for 6 cycles. The clinical efficacy, changes of serum tumor markers, incidence of adverse reactions, 1-year mortality rate of the two groups were counted and compared.Results:The distribution of clinical efficacy grades in the two groups was significantly different ( Z=4.489, P=0.042), and the total effective rate of the experimental group was 63.33% (38/60), which was higher than that of 45.00% (27/60) in the control group ( χ2=4.062, P=0.044). The levels of carbohydrate antigen 125 (CA125), carbohydrate antigen 19-9 (CA19-9), carcino-embryonic antigen (CEA) in the experimental group after treatment were (30.01±6.05) U/ml, (40.38±7.61) U/ml and (16.85±3.08) ng/ml respectively, which in the control group were (45.83±6.91) U/ml, (48.89±8.05) U/ml and (20.20±4.18) ng/ml respectively. The levels of CA125, CA19-9, CEA in both groups after treatment decreased compare with those before treatment, which in the experimental group after treatment were lower than those in the control group, with statistically significant differences ( t=13.343, P<0.001; t=5.951, P<0.001; t=4.998, P<0.001). The incidences of liver dysfunction, renal dysfunction, leukopenia, thrombocytopenia, nausea/vomiting, diarrhea, oral mucositis and total adverse reaction in the experimental group were 8.33% (5/60), 5.00% (3/60), 6.67% (4/60), 6.67% (4/60), 8.33% (5/60), 1.67% (1/60), 3.33% (2/60), 40.00% (24/60), which were 6.67% (4/60), 3.33% (2/60), 8.33% (5/60), 6.67% (4/60), 8.33% (5/60), 0 (0/60), 1.67% (1/60), 35.00% (21/60) in the control group, without statistically significant differences ( χ2=0.000, P=1.000; χ2=0.000, P=1.000; χ2=0.000, P=1.000; χ2=0.134, P=0.714; χ2=0.109, P=0.741; P=1.000; χ2=0.000, P=1.000; χ2=0.320, P=0.572). After 1 year of following-up, the mortality rate of the control group was 8.33% (5/60), and the mortality rate of the experimental group was 5.00% (3/60), and there was no significant difference between the two groups ( χ2=0.134, P=0.714). Conclusion:Berberine hydrochloride combined with epirubicin and cisplatin is effective in treatment of advanced EC, which can decrease tumor marker levels, and it is safe and reliable of clinical reference.